Hofseth Biocare’s Breakthrough in Prostate Cancer

Hofseth Biocare ASA (HOFBF) has released an update.

Hofseth Biocare ASA’s subsidiary HBC Immunology has reported positive results from prostate cancer treatment studies using its leading peptide FT-002a in an oral formulation with standard hormonal therapy, showing enhanced anti-tumor activity and a reduction in biomarkers of free iron. The findings suggest FT-002a could improve the effectiveness of cancer treatments. The company aims to submit an Investigational New Drug (IND) application for its oral co-therapy in the fourth quarter of 2025.

For further insights into HOFBF stock, check out TipRanks’ Stock Analysis page.